A client is taking pyridostigmine for muscle weakness associated with myasthenia gravis. The nurse educates the client on which possible cholinergic side effects associated with this medication? (Select all that apply)

Choice A reason: Tachycardia is an increase in heart rate, which is not typically associated with the cholinergic effects of pyridostigmine. Cholinergic medications usually stimulate the parasympathetic nervous system, which can lead to decreased heart rate (bradycardia) rather than an increase. Therefore, tachycardia is not a relevant side effect of pyridostigmine. Choice B reason: Dry mouth is usually associated with anticholinergic medications, which inhibit the action of acetylcholine, leading to reduced secretion production. Pyridostigmine, being a cholinergic agent, would more likely cause an increase in salivary secretion rather than dry mouth. Therefore, dry mouth is not a typical side effect of pyridostigmine. Choice C reason: Excessive sweating is a common cholinergic side effect due to the stimulation of sweat glands by acetylcholine. Pyridostigmine enhances cholinergic activity, which can lead to increased sweating as part of the parasympathetic response. This side effect is consistent with the expected physiological effects of cholinergic medications. Choice D reason: Bradycardia, or a decreased heart rate, is a potential side effect of pyridostigmine due to its cholinergic effects. By increasing acetylcholine levels, pyridostigmine enhances parasympathetic activity, which can slow down the heart rate. Monitoring for bradycardia is important in patients taking cholinergic medications like pyridostigmine. Choice E reason: Excessive lacrimation, or tearing, is another cholinergic side effect. Pyridostigmine stimulates muscarinic receptors, leading to increased secretion from various glands, including the lacrimal glands. This results in increased tear production, making it a relevant side effect to discuss with patients taking cholinergic medications.